Karius is leading the paradigm shift towards the use of genomics for infectious disease diagnostics. For decades, diagnostic testing for infections had seen little innovation when compared to other medical innovations. Karius CEO, Dr. Kertesz, and his colleagues at Stanford discovered a revolutionary new method to provide genomic insights for infectious diseases using cell-free DNA. From a simple blood draw, the Karius Test enables clinicians to deliver a potentially life-saving diagnosis. By combining next-generation DNA sequencing with machine learning, the Karius platform provides a rapid and comprehensive view of the infection profile of each and every patient, without requiring an invasive biopsy.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):